Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study...

Area of Science:

• Cardiology
• Atherosclerosis research
• Public health

Background:

• Discrepancies exist in LDL-C targets between ACC/AHA and ESC/EAS guidelines for ASCVD patients.
• The DA VINCI study investigated residual cardiovascular risk in ASCVD patients on lipid-lowering therapy.
• Understanding the impact of different LDL-C goals is crucial for optimizing patient outcomes.

Purpose of the Study:

• To simulate the relative and absolute risk reductions achievable by meeting ACC/AHA versus ESC/EAS LDL-C goals in ASCVD patients.
• To compare the potential benefits of stricter LDL-C targets on cardiovascular risk.
• To analyze the gap in LDL-C achievement within current treatment paradigms.

Main Methods:

• The DA VINCI study, a cross-sectional observational study, analyzed data from 2039 patients across 18 European countries on lipid-lowering therapy.
• Ten-year cardiovascular risk was predicted for patients with atherosclerotic cardiovascular disease (ASCVD).
• LDL-C reductions needed to reach <70 mg/dl (ACC/AHA goal) and <55 mg/dl (ESC/EAS goal) were calculated, and relative and absolute risk reductions (RRRs and ARRs) were simulated.

Main Results:

• 61% of patients did not achieve the LDL-C goal of <70 mg/dl.
• For patients with baseline LDL-C ≥70 mg/dl, median reductions of 24 mg/dl and 39 mg/dl were required to reach <70 mg/dl and <55 mg/dl, respectively.
• Achieving ESC/EAS goals simulated RRRs of 22% and ARRs of 6%, compared to 14% RRR and 4% ARR for ACC/AHA goals.

Conclusions:

• In ASCVD patients, adhering to ESC/EAS LDL-C goals (<55 mg/dl) could provide an additional 2% absolute risk reduction over 10 years compared to the ACC/AHA approach (<70 mg/dl).
• Stricter LDL-C targets may be associated with greater cardiovascular risk mitigation.
• Further research may be warranted to explore the clinical implications of guideline differences.